Atopic Dermatitis (AD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Atopic dermatitis (AD) is a chronic inflammatory skin disease of multifactorial etiology characterized by age-specific skin lesions, xerosis, and highly pruritic outbreaks. Usually starting in early childhood, AD significantly reduces patients’ quality of life. Patients with AD are more susceptible to developing allergic diseases and frequently suffer from multimorbidity. Multiple studies link AD during infancy to the future appearance of asthma and allergic rhinitis, with 80% of patients eventually developing either of them or both. Food allergies occur in 35% of children with AD, and cutaneous infections and keratoconjunctivitis are more frequent than in the general population.
·
According to the Thelansis research, atopic
dermatitis (AD) globally affects 15%–20% of children and 1%–3% of adults. These
prevalence figures are growing worldwide and show clear geographical variances;
AD is more frequent in industrialized and high-income countries than in
agriculture-based ones with low incomes.
·
The most frequent chronic comorbidities in
children with AD of all ages and for both sexes were asthma (13.1%),
psychosocial disorders (7.9%), visual impairment (7.8%), congenital anomalies
of limbs (5.8%), and developmental disorders (3.2%), among others. All these
comorbidities were more prevalent in the population with AD. Upper respiratory
tract infections (54.4%), otitis media (12.8%), conjunctivitis (10.1%), and
pharyngitis (7.9%) were amongst the most prevalent acute conditions in this
atopic cohort.
Thelansis’s “Atopic Dermatitis (AD)
Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Atopic
Dermatitis (AD) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Atopic Dermatitis (AD) across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Atopic Dermatitis (AD) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment